A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.

ABSTRACT:

Purpose

Selinexor is the first selective inhibitor of nuclear export to be approved for the treatment of relapsed or refractory multiple myeloma (MM). Currently, there are no known genomic biomarkers or assays to help select MM patients at higher likelihood of response to selinexor. Here, we aimed to characterize the transcriptomic correlates of response to selinexor-based therapy.

Methods

We performed RNA sequencing on CD138+ cells from the bone marrow of 100 patients with MM who participated in the BOSTON study, followed by differential gene expression and pathway analysis. Using the differentially expressed genes, we used cox proportional hazard models to identify a gene signature predictive of response to selinexor, followed by validation in external cohorts.

Results<

SUBMITTER: Restrepo P 

PROVIDER: S-EPMC10530420 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature